On 2026-03-26, Interim CFO William A. Sullivan announced his intention to resign, effective 2026-03-30. On 2026-03-26, Director Alison A. Cornell resigned from the Board and all committees, effective immediately. Both resignations are tied to cost-cutting measures, including the decision to deregister securities and cease public reporting, with no disagreements on company matters. On 2026-03-27, ZIVO announced plans to file Form 15 on or around 2026-03-30 to deregister its securities, suspend Exchange Act reporting, and voluntarily delist from OTC markets. Upon filing Form 15, obligations to file Forms 10-K, 10-Q, and 8-K will immediately cease. Management cites significant reductions in legal, accounting, audit, insurance, and administrative costs as a primary rationale, redeploying resources to core operations. The CEO anticipates meaningful near-term revenue from the AgTech product line via an established distribution partner and expects positive cash flow for the first time due to lower operating costs. Animal Health programs: major global animal health companies are conducting internal due diligence on a non-antibiotic immune-modulating technology; production, yield, dose titration, and interference studies are underway with licensing talks anticipated after data availability. Avian Influenza: The University of Georgia plans to use ZIVO’s product in USDA-funded studies addressing poultry industry challenges. Governance and alignment: Board compensation has been eliminated; any Board investments occur at full market price; the CEO is investing personal capital.